JMI SENTRY Antimicrobial Surveillance Program
Monitor emerging antimicrobial resistance patterns through our proven global network, established in 1997. Get standardized resistance data from 150+ medical centers, while reducing costs through our consortium model. Trust the world's longest-running surveillance program for both new drug development and post-marketing monitoring, with comprehensive data collection across 35+ countries.
What is JMI SENTRY Antimicrobial Surveillance Program at Element?
Antimicrobial surveillance monitors pathogen resistance patterns to guide drug development and treatment decisions. The JMI SENTRY program, now part of Element, collects and analyzes approximately 40,000 clinical isolates annually using reference broth microdilution methods, delivering standardized, high-quality data for both new drug development and post-marketing monitoring requirements.
What Can Element Offer You For JMI SENTRY Antimicrobial Surveillance Program?
Key tests offered
Key tests offered
We perform comprehensive antimicrobial susceptibility testing using reference broth microdilution methods, aligned with both CLSI and EUCAST breakpoints. Our advanced testing capabilities include:
- Resistance mechanism detection through whole genome sequencing
- Real-time monitoring of resistance patterns
- Trend analysis of antimicrobial resistance patterns
- Consecutive isolate collection by infection site
Components and materials we test
Components and materials we test
We analyze clinical isolates from a wide range of infection types through our prevalence-based collection approach. Each year, we process approximately 40,000 bacterial and fungal isolates from bloodstream, respiratory, skin and soft tissue, urinary tract, pneumonia, intra-abdominal, and invasive fungal infections. Our consecutive collection process ensures representative sampling across all infection types.
Methods and solutions offered
Methods and solutions offered
Our consortium-based model offers flexible participation options for complete or partial geographic coverage. We provide customizable programs for specific pathogens or indications while maintaining standardized testing methods. This approach allows you to focus on particular geographic regions, pathogen types, or specific indications while benefiting from our established support network.
For you, this means:
- Isolates are consecutively collected by site of infections
- Susceptibility testing by reference broth microdilution methods
- CLSI and EUCAST breakpoints
- Real-time data monitoring for trend analysis of antimicrobial resistance patterns
- Resistance mechanism detection by whole genome sequencing
Which labs offer this service
Which labs offer this service
Testing is centralized at JMI Labs, now Element Iowa City, leveraging our extensive two-decade experience in antimicrobial surveillance studies. Element’s team operates from Life Sciences hubs across the world, providing global access to our expert capabilities. Find out where your nearest Life Sciences hub is on our Locations Page.
Worldwide surveillance network
Worldwide surveillance network
Our established network of 150+ medical centers across 35+ countries enables comprehensive monitoring of resistance patterns with real-time data access and trend analysis. This prevalence-based approach helps guide local therapy decisions, alerts the scientific community to potential threats, and steers antimicrobial research and development.
Standards we test to and what we test
- CLSI breakpoints
- EUCAST breakpoints
Clinical isolates by infection type:
- Bloodstream infections
- Skin and soft tissue infections
- Respiratory tract infections
- Urinary tract infections
- Pneumonia-related pathogens
- Intra-abdominal infections
- Invasive fungal infections
Your Challenges, Our Solutions
Worldwide resistance monitoring delivered
Efficient surveillance through shared resources
Advanced threat detection and monitoring
Seamless regulatory compliance
Why Choose Element
Global surveillance network
Proven monitoring experience
Customizable programs
Cost-effective approach
40k+ Clinical isolates tested annually
25+ Years of continuous surveillance monitoring
150+ Medical centers in surveillance network
35+ Countries providing resistance data
Frequently asked questions
What is SENTRY?
The SENTRY Antimicrobial Surveillance Program was established in 1997 and now is one of the longest-running antimicrobial surveillance programs in the world. SENTRY monitors worldwide pathogens and the changes in resistance patterns over time through centralized testing and utilizing reference susceptibility methods. SENTRY focuses on recruiting medical centers and hospital sites to participate each calendar in submitting organisms through a prevalence-based approach across a number of different types of infections. The study design collects clinical isolates under the following objectives: bloodstream, skin and soft tissue, respiratory, urinary tract, pathogens from patients hospitalized with pneumonia, intra-abdominal and invasive fungal infections. This prevalence based-approach requirement is critically important to measure the resistance patterns that guide local therapy, alert the scientific community of potential growing threats, and to steer antimicrobial research and development.
How can hospitals participate?
We recruit sites based on geography. The majority of our sites are in the United States and Europe, but we have a significant presence in Latin America, parts of Asia, and the Western Pacific.
Can unique surveillance requirements be accommodated?
Clients that would like a more tailored surveillance program, such as wanting a unique set of sites to be recruited or a certain set of organisms within their approved label of indicated species, can still participate in SENTRY. We would employ a hybrid approach. Element will take your preferred study parameters and create a special objective for SENTRY, achieving a unique program for you within our established support network.
How can my drug be incorporated in the program?
New compounds and other agents can be integrated into the SENTRY platform by establishing agreements and transferring compounds at the beginning of the calendar year. Element bears the costs of the entire program. Each client only contracts for their desired surveillance data, such as geography or specific types of infections or pathogens, resulting in lower costs due to a shared platform approach.
How can I access the public data set?
Element maintains a public SENTRY dataset that provides valuable historical and current resistance data. You can access this resource through our SENTRY Public Dataset portal.
Explore our global network of labs and find your nearest location
VIEW ALL LOCATIONSRelated services
Drug Discovery and Development
Element's CDMO services offer tailored drug discovery and development solutions, helping you reduce costs, accelerate timelines, and advance clinical trials with expert support at every stage.
Microbiological Development and Quality Control Testing Services
Element's lab provides specialist microbiology testing services and quality control for drug products that support all phases of product and process development and help to maintain product integrity.